Nautilus Biotechnology, Inc.
NAUT· Nasdaq
NAUTNautilus Biotechnology, Inc.
Filed Aug 2, 2023 · 10-Q · 33 days after period end · 0001808805-23-000069
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Net Income | -$15.81M | -$14.69M | -$10.71M | -$3.36M |
| EPS Diluted | -$0.13 | -$0.12 | -$0.19 | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nautilus Biotechnology, Inc. · CIK 1808805 · Engraved from SEC EDGAR
ended Jun 30, 2023 · filed Aug 2, 2023 · 33 d after period end
